Dr. Jakob Magolan

Associate Professor, Dept. of Biochemistry and Biomedical Science

Boris Family Chair of Drug Discovery

Associate Member, Dept. of Chemistry and Chemical Biology

Member, Michael G. DeGroote Institute for Infectious Disease Research

 

Email: magolanj@mcmaster.ca

Tel: 905-525-9140 ext. 22268

Office: Room 2234, MDCL (Michael Degroote Center for Learning and Discovery)

Mail:  1200 Main Street West, MDCL 2306 
Hamilton, ON, L8N 3Z5, Canada

About Dr. Magolan

Dr. Magolan was born in Wloclawek, Poland and raised in Kitchener, Canada.   He completed his undergraduate studies at Queen's University in Kingston, Canada, earning degrees in Chemistry and in Physical and Health Education, while playing some volleyball. As an undergraduate student, he worked with Prof. Robert Lemieux on the synthesis of new liquid crystals.  He obtained his PhD in 2007 from Western University, London, Canada, under the mentorship of Prof. Michael Kerr, working on natural products synthesis and synthetic methodology.  He then worked as postdoctoral researcher at the Griffith Institute for Drug Discovery in Brisbane, Australia in the field of anti-pancreatic cancer medicinal chemistry under guidance of Prof. Mark Coster.   Jake began his independent career in 2010 in the Department of Chemistry at University of Idaho where he established an NSF-funded research program in synthetic methodology and was the department's primary instructor of organic chemistry.   He earned Tenure and Promotion to Associate Professor at the University of Idaho.  He received recognition for his commitment to undergraduate research and education.  In 2017, Jake moved from Idaho to McMaster University to become an Associate Professor in Department of Biochemistry and Biomedical Sciences and the inaugural holder of the Boris Family Endowed Chair of Drug Discovery.  At McMaster, Dr. Magolan maintains an interest in methodologies that enable efficient organic synthesis but his program is now primarily engaged in interdiciplinary collaborative research focused on drug discovery and hit-to-lead medicinal chemistry in a range of therapeutic areas.